Novo Nordisk A/S - Share repurchase programme

Udgivet den 30-05-2016  |  kl. 13:27  |  

Bagsværd, Denmark, 30 May 2016 - On 3 February 2016, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 3 February 2016.

Under the programme initiated 29 April 2016, Novo Nordisk will repurchase B shares for an amount up to DKK 3.5 billion in the period from 29 April 2016 to 3 August 2016.

Since the announcement as of 19 May 2016, the following transactions have been made under the programme:

  Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 1,642,000   587,842,892
19 May 2016 160,000 358.51 57,362,224
20 May 2016 158,000 359.30 56,768,768
23 May 2016 145,000 356.92 51,753,226
24 May 2016 150,000 361.06 54,158,385
25 May 2016 145,000 375.17 54,400,201
26 May 2016 150,000 373.18 55,977,090
27 May 2016 140,000 371.46 52,004,610
Accumulated under the programme 2,690,000   970,267,396

With the transactions stated above, Novo Nordisk owns a total of 14,767,645 B shares of DKK 0.20, corresponding to 0.6% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,550,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14 billion during a 12-month period beginning 3 February 2016. As of 27 May 2016, Novo Nordisk has repurchased a total of 12,836,000 B shares equal to a transaction value of DKK 4,599,822,121.

Further information

Media:    
Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com
     


Company announcement no 43 / 2016


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

HUG#2016462

\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

17:53 DSV har store udskiftninger på vej i bestyrelsen - tre er på vej ud
17:45 Europa/lukning: Optur for fransk chipaktie i rødt marked
17:26 McKinsey indgår milliardforlig i sag om rådgivning om opioider
17:07 Fredagens aktier: Nedtur til Novo Nordisk og medicinalsektor trækker C25 i rødt
17:03 Fredagens obligationer: Renten steg efter sænkede renter fra ECB og frem mod møde i USA
16:45 Zelenskyj mødes med EU-ledere efter spekulationer om fredsstyrker
16:35 Amerikansk møbelforhandler sendt i vejret efter opjustering
15:44 Gældstynget olieselskab sendes ned efter forhandlinger med konkurrent om salg
15:41 Schweizisk softwaredistributør langt i forhandlinger om at overtage norsk konkurrent
15:40 USA/åbning: Broadcom skyder op i grøn amerikansk handelsstart - chipaktier følger med
14:54 Amerikanske Evgo flyver op i formarkedet efter tilsagn om milliardlån
14:40 USA/tendens: Chipaktier står til solid fredag - Broadcom stiger tocifret
14:32 Tørlastindekset Baltic Dry er nu faldet 36 pct. den senste måned
14:12 Tryg indgår ny partneraftale med FDM: Aftalen løber nu til udgangen af 2030
13:45 Djurslands Bank udsteder 100 mio. kr.-obligation til polstring af kapital
13:02 Europa/aktier: Fransk chipaktie har optur i marked med små udsving
11:47 Aktier/middag: Sur dag for medicinalaktier trækker C25 i rødt
11:21 Obligationer/middag: Rentestigning frem mod weekenden - nyt rentemøde i fokus
11:03 Eurozonens industriproduktion var stabil i oktober og helt som ventet
10:38 Vestjysk Bank indgår låneaftale på 550 mio. kr.